This report was first published by Endpoints News. To see the original version, click here
Eli Lilly will buy Orna Therapeutics to get a hold of its immune system-resetting pipeline and enter the in vivo CAR-T cell therapy race.
The Monday morning acquisition amounts to as much as $2.4 billion, a total value that would represent the largest buyout of an in vivo cell therapy company to date. The companies didn’t break down the split between an upfront payment and biobucks.
您已阅读14%（474字），剩余86%（2929字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。